

PRESS RELEASE

MabGenesis announces collaboration with Nippon Soda Co., Ltd. to discover and develop novel monoclonal antibodies for use in dogs and cats

Yokohama, Japan, September 25, 2025 – MabGenesis Inc. (“MabGenesis”), a private biopharmaceutical company headquartered in Yokohama, Japan, and Nippon Soda Co., Ltd. (“Nippon Soda”) today announced that they have entered into a collaboration to discover and develop novel monoclonal antibodies for potential therapeutic treatments of dogs and cats.

Under the agreement, MabGenesis will apply its unique platform to the discovery of candidate antibodies. Nippon Soda will have the right to develop and commercialize products resulting from the collaboration. Terms of the agreement were not disclosed.

"We are excited to partner with Nippon Soda as we feel we bring complementary expertise to this collaboration," said Katsuhiro Shinjo, DVM, PhD, Chief Executive Officer of MabGenesis. "The combination of our innovative discovery platform, MOURA Library and IMPACT, and the development capability of Nippon Soda has the potential for the discovery and development of innovative therapeutic antibodies bringing benefits to companion animal health."

"Through our collaboration with MabGenesis, we aim to integrate their innovative technologies with our expertise to achieve early commercialization," said Makoto Kato, Executive Officer and General Manager of Chemical Products Division, Nippon Soda. "MabGenesis's MOURA library, which provides high-performance monoclonal antibodies that are difficult to obtain with conventional technologies, is innovative, and we will work together with MabGenesis to realize the practical application of veterinary monoclonal antibody therapeutics, utilizing our expertise cultivated over many years."

About MabGenesis Inc.

MabGenesis is a biopharmaceutical startup that delivers first-in-class and best-in-class therapeutic monoclonal antibodies using technologies established by 30+ years of academic research. By using the innovative technology platform, high-quality phage display antibody libraries (MOURA Libraries) and efficient antibody isolation technology (IMPACT), MabGenesis makes it possible to isolate species-specific monoclonal antibodies rapidly and efficiently. MabGenesis is a private company headquartered in Yokohama, Japan.

For more information, visit <https://mabgenesis.com/en> and connect with us on [LinkedIn](#).

MabGenesis Inc. press contact

Yuichiro Shibazaki – Chief Business Officer
Email: info@mabgenesis.com
Phone: + 81 80 5926 4677

About Nippon Soda Co., Ltd.

Since its founding in 1920, Nippon Soda has accumulated unique technology and know-how to provide highly functional, high-added-value chemical products, including agrochemicals, pharmaceuticals, and specialty chemicals. As a company that handles chemical substances, we have always been conscious of the concept of responsible care and have conducted business activities that take into consideration the environment, safety, quality, and health. We will continue to create new value through our original technologies and products and contribute to creating a prosperous society.

For more information, visit <https://www.nippon-soda.co.jp/e/>.

Nippon Soda press contacts

Corporate Communication Sec. General Affairs Dept.

Email: info@nissogr.com
